An economic evaluation of manic-depressive illness--1991.
paper
Cited
Public
Unavailable
- Authors
- Wyatt, R J; Henter, I
- Year
- 1995
- Journal
- Social psychiatry and psychiatric epidemiology
- PMID
- 7482006
- DOI
- 10.1007/BF00789056
- PMCID
- PMC4301427
In 1991, the costs for manic-depressive illness, which has a lifetime prevalence of 1.3% among adult Americans, totaled $45 billion. Costs were broken down into their direct and indirect components. Direct costs totaling $7 billion consist of expenditures for inpatient and outpatient care, which are treatment related, as well as nontreatment-related expenditures such as those for the criminal justice system used by individuals with manic-depressive illness. Indirect costs, which were $38 billion, include the lost productivity of both wage-earners ($17 billion) and homemakers ($3 billion), individuals who are in institutions ($3 billion) or who have committed suicide ($8 billion), and caregivers who take care of manic-depressive family members ($6 billion). The method for determining each expenditure is provided, and the implications of these staggering costs are discussed. These calculations rely heavily on methods and data bases that were developed for the accompanying paper on the costs of schizophrenia.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Amygdala reactivity to threat, negative facial perception, and risk of future psychiatric hospitalizations: a longitudinal study in major depressive and bipolar disorders. | Miskowiak KW et al. | β | 2026 | β |
| Differences in the Efficacy of Cognitive Function Treatment Related to Functional Patterns in the Frontal-Limbic Network in Patients With Bipolar Disorder. | Li S et al. | β | 2026 | β |
| Challenges in the development of treatment guidelines for bipolar disorder. | Fountoulakis KN et al. | β | 2025 | β |
| Prediction of medical admissions after psychiatric inpatient hospitalization in bipolar disorder: a retrospective cohort study. | Miola A et al. | β | 2024 | β |
| A Prospective Comparison of Bipolar I and II Subjects with and without Comorbid Cannabis Use Disorders from the COGA Dataset. | Preuss UW et al. | β | 2023 | β |
| Job retention for people with bipolar disorder: A qualitative analysis. | Marion-Paris E et al. | β | 2023 | β |
| Predictors of Employment Status for Persons with Bipolar Disorder. | Lu SJ et al. | β | 2022 | β |
| Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force. | Miskowiak KW et al. | β | 2022 | β |
| The hidden link between circadian entropy and mental health disorders. | Alachkar A et al. | β | 2022 | β |
| Relationship Between Mood Episode and Employment Status of Outpatients with Bipolar Disorder: Retrospective Cohort Study from the Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Clinics (MUSUBI) Project. | Konno Y et al. | β | 2021 | β |
| The mindfulness trajectories of addressing suicidal behaviour: A systematic review. | Raj S et al. | β | 2021 | β |
| Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders. | Ayyagari R et al. | β | 2020 | β |
| Economic evaluations of non-pharmacological interventions and cost-of-illness studies in bipolar disorder: A systematic review. | Kraiss JT et al. | β | 2020 | β |
| Patient-evaluated cognitive function measured with smartphones and the association with objective cognitive function, perceived stress, quality of life and function capacity in patients with bipolar disorder. | Faurholt-Jepsen M et al. | β | 2020 | β |
| The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review. | Bessonova L et al. | β | 2020 | β |
| Neuronal underpinnings of cognitive impairment and - improvement in mood disorders. | Miskowiak KW et al. | β | 2019 | β |
| Unrecognized bipolar disorder in patients with depression managed in primary care: A systematic review and meta-analysis. | Daveney J et al. | β | 2019 | β |
| Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial. | Petersen JZ et al. | β | 2018 | β |
| GSK3Ξ²: a plausible mechanism of cognitive and hippocampal changes induced by erythropoietin treatment in mood disorders? | Inkster B et al. | β | 2018 | β |
| Neural and Behavioral Predictors of Treatment Efficacy on Mood Symptoms and Cognition in Mood Disorders: A Systematic Review. | Seeberg I et al. | β | 2018 | β |
| The development and psychometric properties of the bipolar disorders knowledge scale. | Stump TA et al. | β | 2018 | β |
| The economic burden of bipolar I disorder in the United States in 2015. | Cloutier M et al. | β | 2018 | β |
| ANK3 gene polymorphisms and bipolar disorder: a meta-analysis. | Roby Y | β | 2017 | β |
| Could EPO studies improve mood disorder treatment strategies? | Miskowiak KW | β | 2017 | β |
| The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of Guidelines. | Fountoulakis KN et al. | β | 2017 | β |
| Effects of Omega-3 Supplement in the Treatment of Patients with Bipolar I Disorder. | Shakeri J et al. | β | 2016 | β |
| Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases. | MacEwan JP et al. | β | 2016 | β |
| Predictors of the discrepancy between objective and subjective cognition in bipolar disorder: a novel methodology. | Miskowiak KW et al. | β | 2016 | β |
| A Lifetime Prevalence of Comorbidity Between Bipolar Affective Disorder and Anxiety Disorders: A Meta-analysis of 52 Interview-based Studies of Psychiatric Population. | Nabavi B et al. | β | 2015 | β |
| Cost-of-illness studies for bipolar disorder: systematic review of international studies. | Jin H et al. | β | 2015 | β |
| Effects of Erythropoietin on Hippocampal Volume and Memory in Mood Disorders. | Miskowiak KW et al. | β | 2015 | β |
| Epilepsy and bipolar disorder. | Knott S et al. | β | 2015 | β |
| Impact of initiation of asenapine on patterns of utilization and cost of healthcare resources associated with the treatment of bipolar I disorder. | Chitnis A et al. | β | 2015 | β |
| Management of bipolar disorders in women by nonpharmacological methods. | Naik SK | β | 2015 | β |
| Quality of care for Medicaid-enrolled youth with bipolar disorders. | Fontanella CA et al. | β | 2015 | β |
| Cognitive behavioral therapy for insomnia in euthymic bipolar disorder: study protocol for a randomized controlled trial. | Steinan MK et al. | β | 2014 | β |
| Comparative study of cost of care of outpatients with bipolar disorder and schizophrenia. | Somaiya M et al. | β | 2014 | β |
| Correlates of real world executive dysfunction in bipolar I disorder. | Peters AT et al. | β | 2014 | β |
| Dietary intake and plasma metabolomic analysis of polyunsaturated fatty acids in bipolar subjects reveal dysregulation of linoleic acid metabolism. | Evans SJ et al. | β | 2014 | β |
| Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. | Tse S et al. | β | 2014 | β |
| The prevalence and burden of bipolar depression. | Miller S et al. | β | 2014 | β |
| The relationship between neurotrophins and bipolar disorder. | Wu R et al. | β | 2014 | β |
| Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates. | Lev-Ran S et al. | β | 2013 | β |
| Employment outcomes in people with bipolar disorder: a systematic review. | Marwaha S et al. | β | 2013 | β |
| High-risk behaviour in hypomanic states. | Fletcher K et al. | β | 2013 | β |
| Patterns of atypical antipsychotic therapy use in adults with bipolar I disorder in the USA. | Chen W et al. | β | 2013 | β |
| Predictors of employment in bipolar disorder: a systematic review. | Gilbert E et al. | β | 2013 | β |
| Prevalence, chronicity, burden and borders of bipolar disorder. | Fagiolini A et al. | β | 2013 | β |
| Risk of hypertension in patients with bipolar disorder in Taiwan: a population-based study. | Chien IC et al. | β | 2013 | β |
| Sexually dimorphic, developmental, and chronobiological behavioral profiles of a mouse mania model. | Saul MC et al. | β | 2013 | β |
| The effect of personality dimensions on functional outcomes in mood disorders. | Leen J et al. | β | 2013 | β |
| The impact of child sexual abuse on the course of bipolar disorder: a systematic review. | Maniglio R | β | 2013 | β |
| Customization in prescribing for bipolar disorder. | Hodgkin D et al. | β | 2012 | β |
| Determinants of occupational and residential functioning in bipolar disorder. | Depp CA et al. | β | 2012 | β |
| Diagnosing bipolar disorder in the community setting. | Donohue AW | β | 2012 | β |
| Medical costs and vasculometabolic comorbidities among patients with bipolar disorder in Taiwan - a population-based and matched-control study. | Hsieh MH et al. | β | 2012 | β |
| Quetiapine: a pharmacoeconomic review of its use in bipolar disorder. | Plosker GL | β | 2012 | β |
| Treatment use and costs among privately insured youths with diagnoses of bipolar disorder. | Dusetzina SB et al. | β | 2012 | β |
| Are screening scales for bipolar disorder good enough to be used in clinical practice? | Zimmerman M et al. | β | 2011 | β |
| Bipolar disorder patients have similar levels of education but lower socio-economic status than the general population. | Schoeyen HK et al. | β | 2011 | β |
| Direct costs of bipolar disorder versus other chronic conditions: an employer-based health plan analysis. | Williams MD et al. | β | 2011 | β |
| Estimation of resource utilisation difference between lithium and valproate treatment groups from the VALID study. | Li SC et al. | β | 2011 | β |
| Metabolic syndrome in Tunisian bipolar I patients. | Ezzaher A et al. | β | 2011 | β |
| Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review. | Sacchetti E et al. | β | 2011 | β |
| Reliability and validity of the Chinese Version of the Mood Disorder Questionnaire. | Lin CJ et al. | β | 2011 | β |
| Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder. | Woodward TC et al. | β | 2010 | β |
| Early life stressors and genetic influences on the development of bipolar disorder: the roles of childhood abuse and brain-derived neurotrophic factor. | Liu RT | β | 2010 | β |
| Healthcare costs of atypical antipsychotic use for patients with bipolar disorder in a Medicaid programme. | Qiu Y et al. | β | 2010 | β |
| Indirect costs associated with nonadherence to treatment for bipolar disorder. | Bagalman E et al. | β | 2010 | β |
| Overdiagnosis of bipolar disorder and disability payments. | Zimmerman M et al. | β | 2010 | β |
| Pattern of healthcare resource utilization and direct costs associated with manic episodes in Spain. | Tafalla M et al. | β | 2010 | β |
| Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder. | Squassina A et al. | β | 2010 | β |
| The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). | Bond DJ et al. | β | 2010 | β |
| The cost of relapse for patients with a manic/mixed episode of bipolar disorder in the EMBLEM study. | Hong J et al. | β | 2010 | β |
| Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). | Bond DJ et al. | β | 2010 | β |
| Workplace productivity, employment issues, and resource utilization in patients with bipolar I disorder. | McMorris BJ et al. | β | 2010 | β |
| Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar I disorder. | Woodward TC et al. | β | 2009 | β |
| Difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations. | Bhosle M et al. | β | 2009 | β |
| Functional neuroimaging studies of bipolar disorder: examining the wide clinical spectrum in the search for disease endophenotypes. | Pan L et al. | β | 2009 | β |
| Health and economic burden of metabolic comorbidity among individuals with bipolar disorder. | Centorrino F et al. | β | 2009 | β |
| Psychiatric admissions and hospitalization costs in bipolar disorder in Sweden. | Osby U et al. | β | 2009 | β |
| Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. | Hassan M et al. | β | 2009 | β |
| The phenomenology of bipolar disorder: what drives the high rate of medical burden and determines long-term prognosis? | Soreca I et al. | β | 2009 | β |
| The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. | Lage MJ et al. | β | 2009 | β |
| Treating bipolar disorder in the primary care setting: the role of aripiprazole. | Manning JS et al. | β | 2009 | β |
| Bipolar disorder and suicide: research synthesis and clinical translation. | McIntyre RS et al. | β | 2008 | β |
| Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. | Fagiolini A et al. | β | 2008 | β |
| Burden of bipolar depression: impact of disorder and medications on quality of life. | Michalak EE et al. | β | 2008 | β |
| Clinical and economic effects of unrecognized or inadequately treated bipolar disorder. | Keck PE et al. | β | 2008 | β |
| Decision making in bipolar disorder: a cognitive modeling approach. | Yechiam E et al. | β | 2008 | β |
| Development of evidence-based performance measures for bipolar disorder: overview of methodology. | Golden WE et al. | β | 2008 | β |
| Factors associated with treatment nonadherence among US bipolar disorder patients. | Baldessarini RJ et al. | β | 2008 | β |
| Genetics of bipolar disorder. | Escamilla MA et al. | β | 2008 | β |
| Impact of bipolar disorder on the family: utilization and cost of health care resources. | Chatterton ML et al. | β | 2008 | β |
| Impact of remitted substance use disorders on the future course of bipolar I disorder: findings from a clinical trial. | Gaudiano BA et al. | β | 2008 | β |
| Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? | Rao JS et al. | β | 2008 | β |
| Neither single-marker nor haplotype analyses support an association between monoamine oxidase A gene and bipolar disorder. | Huang SY et al. | β | 2008 | β |
| Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. | Soreca I et al. | β | 2008 | β |
| The burden of mental disorders. | Eaton WW et al. | β | 2008 | β |
| The prevalence and correlates of workplace depression in the national comorbidity survey replication. | Kessler RC et al. | β | 2008 | β |
| Antimanic therapies target brain arachidonic acid signaling: lessons learned about the regulation of brain fatty acid metabolism. | Lee HJ et al. | β | 2007 | β |
| Bipolar disorders in Australia. A population-based study of excess costs. | Fisher LJ et al. | β | 2007 | β |
| Developing core sets for persons with bipolar disorder based on the International Classification of Functioning, Disability and Health. | Vieta E et al. | β | 2007 | β |
| Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications. | Gianfrancesco F et al. | β | 2007 | β |
| Identifying functional neuroimaging biomarkers of bipolar disorder: toward DSM-V. | Phillips ML et al. | β | 2007 | β |
| Influence of medication choice and comorbid diabetes: the cost of bipolar disorder in a privately insured US population. | Harley C et al. | β | 2007 | β |
| Manic symptoms and quality of life in bipolar disorder. | Gazalle FK et al. | β | 2007 | β |
| Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder. | Zhu B et al. | β | 2007 | β |
| Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder. | Klok RM et al. | β | 2007 | β |
| Prevalence and correlates of burden among caregivers of patients with bipolar disorder enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder. | Perlick DA et al. | β | 2007 | β |
| Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. | Kessler RC et al. | β | 2007 | β |
| Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care. | Stensland MD et al. | β | 2007 | β |
| The impact of bipolar disorder upon work functioning: a qualitative analysis. | Michalak EE et al. | β | 2007 | β |
| Carbamazepine extended-release capsules in bipolar disorder. | Weisler RH | β | 2006 | β |
| Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes. | Shi L et al. | β | 2006 | β |
| Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. | Kessler RC et al. | β | 2006 | β |
| The clinical history and costs associated with delayed diagnosis of bipolar disorder. | Stang PE et al. | β | 2006 | β |
| [The costs of bipolar disorder]. | Dardennes R et al. | β | 2006 | β |
| The neuropsychology of mood disorders. | Chamberlain SR et al. | β | 2006 | β |
| Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. | McIntyre RS et al. | β | 2005 | β |
| Bipolar disorder and health-related quality of life : review of burden of disease and clinical trials. | Revicki DA et al. | β | 2005 | β |
| Bipolar I and II disorders in a random and representative Australian population. | Goldney RD et al. | β | 2005 | β |
| Burden of illness in bipolar depression. | Manning JS | β | 2005 | β |
| Correlates and consequences of chronic insomnia. | Thase ME | β | 2005 | β |
| Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder. | Chisholm D et al. | β | 2005 | β |
| Epidemiological and clinical aspects of bipolar disorders: controversies or a common need to redefine the aims and methodological aspects of surveys. | Carta MG et al. | β | 2005 | β |
| Epidemiology of bipolar disorders. | Bauer M et al. | β | 2005 | β |
| GABA and glutamate systems as therapeutic targets in depression and mood disorders. | Kendell SF et al. | β | 2005 | β |
| Identifying and improving non-adherence in bipolar disorders. | Colom F et al. | β | 2005 | β |
| Pathways to care for patients with bipolar disorder. | Bhugra D et al. | β | 2005 | β |
| Quality of care measures for the treatment of bipolar disorder. | Duffy FF et al. | β | 2005 | β |
| Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial. | Zhu B et al. | β | 2005 | β |
| The burden on informal caregivers of people with bipolar disorder. | Ogilvie AD et al. | β | 2005 | β |
| Use of polypharmacy and self-reported mood in outpatients with bipolar disorder. | Adli M et al. | β | 2005 | β |
| A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. | Dean BB et al. | β | 2004 | β |
| Economic grand rounds: the economic burden of bipolar disorder. | Stimmel GL | β | 2004 | β |
| Enhancement of treatment adherence among patients with bipolar disorder. | Sajatovic M et al. | β | 2004 | β |
| Quality of life in patients with bipolar I depression: data from 920 patients. | Yatham LN et al. | β | 2004 | β |
| The bipolar patient with comorbid substance use disorder: recognition and management. | Albanese MJ et al. | β | 2004 | β |
| The role of family systems in severe and recurrent psychiatric disorders: a developmental psychopathology view. | Miklowitz DJ | β | 2004 | β |
| The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands. | Hakkaart-van Roijen L et al. | β | 2004 | β |
| Undiagnosed Bipolar Disorder: New Syndromes and New Treatments. | Glick ID | β | 2004 | β |
| Clinical consequences of under-recognized bipolar spectrum disorder. | Dunner DL | β | 2003 | β |
| Costs of bipolar disorder. | Kleinman L et al. | β | 2003 | β |
| Frequency of hospitalisations and inpatient care costs of manic episodes: in patients with bipolar I disorder in France. | de Zelicourt M et al. | β | 2003 | β |
| Genome-wide scan and conditional analysis in bipolar disorder: evidence for genomic interaction in the National Institute of Mental Health genetics initiative bipolar pedigrees. | McInnis MG et al. | β | 2003 | β |
| Impact of ECT on duration of hospitalizations for mania. | Volpe FM et al. | β | 2003 | β |
| Insurance expenditures on bipolar disorder: clinical and parity implications. | Peele PB et al. | β | 2003 | β |
| Pharmacogenetics and mood stabilization in bipolar disorder. | Ruzickova M et al. | β | 2003 | β |
| Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). | Sachs GS et al. | β | 2003 | β |
| Unmet clinical needs in bipolar disorder. | Sachs GS | β | 2003 | β |
| Bipolar disorder. | Bauer M et al. | β | 2002 | β |
| Bipolar disorder. | MΓΌller-Oerlinghausen B et al. | β | 2002 | β |
| Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. | Li J et al. | β | 2002 | β |
| Manic episodes: the direct cost of a three-month period following hospitalisation. | OliΓ© JP et al. | β | 2002 | β |
| Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis. | Stender M et al. | β | 2002 | β |
| Overcoming barriers to reducing the burden of affective disorders. | Wells KB et al. | β | 2002 | β |
| The Mood Disorder Questionnaire: A Simple, Patient-Rated Screening Instrument for Bipolar Disorder. | Hirschfeld RM | β | 2002 | β |
| Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study. | Bauer MS et al. | β | 2001 | β |
| Emerging therapeutic targets in bipolar mood disorder. | Sassi RB et al. | β | 2001 | β |
| Lithium-related genetics of bipolar disorder. | Detera-Wadleigh SD | β | 2001 | β |
| Lithium revisited: savings brought about by the use of lithium, 1970-1991. | Wyatt RJ et al. | β | 2001 | β |
| Lithium treatment at 52. | Schou M | β | 2001 | β |
| Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. | Tondo L et al. | β | 2001 | β |
| Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. | Tondo L et al. | β | 2001 | β |
| Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. | Tondo L et al. | β | 2001 | β |
| The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. | Begley CE et al. | β | 2001 | β |
| The Stanley Foundation Bipolar Treatment Outcome Network. I. Longitudinal methodology. | Leverich GS et al. | β | 2001 | β |
| Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. | Baldessarini RJ et al. | β | 2001 | β |
| Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. | Svarstad BL et al. | β | 2001 | β |
| Health-related quality of life using the SF-36 in patients with bipolar disorder compared with patients with chronic back pain and the general population. | Arnold LM et al. | β | 2000 | β |
| Increases in manic symptoms after life events involving goal attainment. | Johnson SL et al. | β | 2000 | β |
| The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. | Tohen M et al. | β | 2000 | β |
| The use of administrative data to assess quality of care for bipolar disorder in a large staff model HMO. | UnΓΌtzer J et al. | β | 2000 | β |
| Anticonvulsant Use in the Treatment of Bipolar Disorder: A Primer for Primary Care Physicians. | Leo RJ et al. | β | 1999 | β |
| Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications. | Baldessarini RJ et al. | β | 1999 | β |
| Health care utilization and costs among patients treated for bipolar disorder in an insured population. | Simon GE et al. | β | 1999 | β |
| Latency and episodes before treatment: response to lithium maintenance in bipolar I and II disorders. | Baldessarini RJ et al. | β | 1999 | β |
| Natural history and preventative treatment of recurrent mood disorders. | Frank E et al. | β | 1999 | β |
| Signalling pathways in the brain: cellular transduction of mood stabilisation in the treatment of manic-depressive illness. | Manji HK et al. | β | 1999 | β |
| Therapeutic drug monitoring of mood stabilizers in Medicaid patients with bipolar disorder. | Marcus SC et al. | β | 1999 | β |
| Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. | Manji HK et al. | β | 1999 | β |
| Recurrence risk in bipolar manic-depressive disorders after discontinuing lithium maintenance treatment: an overview. | Baldessarini RJ et al. | β | 1998 | β |
| The treated prevalence of bipolar disorder in a large staff-model HMO. | UnΓΌtzer J et al. | β | 1998 | β |
| Effect of lithium maintenance on suicidal behavior in major mood disorders. | Tondo L et al. | β | 1997 | β |